Trial Profile

A Prospective Observational Study of Erivedge Treatment, Effectiveness, and Safety Outcomes in Patients With Advanced Basal Cell Carcinoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vismodegib (Primary)
Indications Basal cell cancer; Basal cell nevus syndrome
Focus Adverse reactions; Therapeutic Use
Acronyms ROSETT
Sponsors Roche

Most Recent Events

08 Oct 2020 Status changed from active, no longer recruiting to completed.
24 Jul 2018 Planned End Date changed from 19 Dec 2020 to 29 Aug 2020.
24 Jul 2018 Planned primary completion date changed from 19 Dec 2020 to 29 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com